M
any studies have demonstrated that monocyte (M) 4 / macrophage (Mac) dysfunctions are pivotal in the development of the dysregulated inflammatory cytokine production typical of trauma patients who develop multiple organ failure and infectious complications (1) (2) (3) (4) (5) (6) . Simultaneous with the often-exaggerated inflammatory response, these patients' M show depressed HLA-DR expression and a failure of Ag-presenting functions, which appears to be correlated with the development of T cell immunosuppression (7) (8) (9) (10) (11) (12) (13) . The most potent APC is the dendritic cell (DC) (14 -18) . Consequently, a DC dysfunction might be causal or accompany some of these postinjury APC deficits. Human blood M can differentiate to immature DC (iDC) under the influence of lymphokines like GM-CSF and IL-4 (17) (18) (19) (20) . These iDC require further maturation by T cell interactions or infectious stimuli to become potent immunostimulatory APC capable of activating naive T cells and required for memory T cell reactivation and maintenance (19 -22) . Alternatively, under other cytokine influences and different in vivo environments, M differentiate to Mac, which have higher potential for inflammatory cytokine production but lower expression of MHC class II and costimulatory molecules, are inefficient APC, and are unable to activate naive T cells (19, (23) (24) (25) . A failure of M-to-iDC differentiation has been described in immunosuppressed Sezary syndrome and multiple myeloma patients and ascribed to their depressed levels of CD11c dendritic precursors (26 -27) . The dysregulated M function seen in some trauma patients could also be related to depressed iDC differentiation and increased Mac differentiation. M differentiation to iDC can be redirected to Mac differentiation by IFN-␥, IL-6, M-CSF, LPS, or IL-10 (20, (23) (24) (25) 28) . LPS and IFN-␥ are thought to mediate this M-to-Mac differentiation switch by increasing M IL-6 and M-CSF production, and down-regulating GM-CSFR expression overbalancing any IL-4 plus GM-CSF (4ϩGM) effect (25) . In this study, M of trauma patients with diminished APC function (defined as depressed MLR-inducing capacity and decreased IL-12 production) were assessed for in vitro differentiation to iDC under the influence of 4ϩGM. Up-regulated expression of CD1a and CD86, increased IL-12 and IL-15 production, as well as DC maturation and MLR induction in allogenic T lymphocyte cultures were also assayed. M-CSF production by MLR-dysfunctional patient M was assessed and found to be elevated. Increased M-CSFR and CD64 expression appeared simultaneously with decreased M GM-CSFR and IL-4R levels in APC-dysfunctional M. Exogenous addition of Ab to M-CSF during DC generation was assessed for improved patient M-to-iDC differentiation. This study is the first investigation of APC-dysfunctional M populations of trauma patients for an in vitro M-to-iDC conversion defect.
Materials and Methods

Studied population
A total of 46 patients admitted to either University of Massachusetts Medical Center or University of Rochester Medical Center were enrolled in the study. There were 40 patients with serious mechanical trauma (injury severity score (ISS), Ͼ17; mean ISS, 38) and 6 patients with thermal trauma (total body surface burn area, Ͼ25%). There were 29 males and 17 females. The mean age was 52.3 years. Patient samples were first collected at least 2 days after trauma to reduce variables related to the initial treatment. Then, sample collection was continued one to two times per week until the day the patient was released or died. Appearance of MLR dysfunction for two consecutive assays was required for classification as APC dysfunctional. Patients (n ϭ 6) whose M had a one-time transient depression were included in the APC-responsive group. Some patients' M data appeared as APC functional at first, and then dysfunctional, as they progressed to a defect over time postinjury. No more than two samples for each patient were included. The exclusion criteria included whole-blood transfusion, immunosuppressive therapy, a history of immunoproliferative disease, or other immunological aberrances. The clinical pathology of the patients was quantitatively compared with M functions, using elevation in the Marshall multiple organ dysfunction syndrome (MODS) score during the 24-h period for which each blood sample was drawn (29) . A Marshall MODS score of Ͼ6 represents significant organ dysfunction and clinical pathology (29) . A normal control sample was tested along with each patient's samples. The control samples were collected from a panel of 48 normal donors (volunteers from hospital and laboratory staff) who had been repeatedly assayed over a 12-mo period to establish their immune response levels and variation parameters. Their mean age was 41 years. Informed consent was obtained from all subjects. The study was approved by the University of Rochester Institutional Review Board.
Isolation of T lymphocytes and M
Thirty milliliters of blood was drawn twice weekly from each patient using existing i.v. lines. Simultaneously, a similar amount of blood was drawn from the control's antecubital vein. PBMC were isolated by centrifugation over a Ficoll-Hypaque gradient and then resuspended in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% FBS (HyClone, Logan, UT), 50 U/ml penicillin G, 50 g/ml streptomycin, 50 g/ml gentamicin, 2.5 g/ml fungizone, 4 mmol/L L-glutamine, 1 mmol/L sodium pyruvate, and 1% of MEM nonessential amino acids (complete medium). All media were supplemented with 20 U/ml polymyxin B (Calbiochem, La Jolla, CA), and the endotoxin level was Ͻ15 pg/ml. T cells were isolated from PBMC using neuraminidase-treated SRBC as described (30) . M were isolated from T cell-depleted PBMC by negative magnetic separation with anti-CD19 beads and anti-CD2 beads according to the manufacturer's instructions (Dynal, Lake Success, NY). A subsequent flow cytometric analysis revealed ϳ83% CD33 ϩ cells in M samples and 95% CD3 positivity in separated T cells. Surface expression of CD126, CD115, IL-4R, GM-CSFR, CD64, and CD11c was evaluated with flow cytometry gating on fresh CD33 ϩ M. CD33 was chosen as a M marker based on its continued expression on Mac, M, and DC, as opposed to CD14, which is down-regulated in DC and may be shed from highly activated M (31-33).
T cell proliferation and lymphokine production
Purified T cells (2 ϫ 10 5 cell/200 l/well) were cultured in a 96-well plate precoated with anti-CD3 and anti-CD4 (1 g/well each; BD PharMingen, San Diego, CA). After 24 h, supernatants were collected for assessment of lymphokine production, whereas proliferation was measured in 72-h culture by [ 3 H]thymidine incorporation assays, as described previously (30) .
In vitro generation of iDC
Isolated M were cultured (3 ϫ 10 6 cells/3 ml/well) in complete medium with 5 ϫ 10 Ϫ5 M 2-ME and 5 ϫ 10 Ϫ2 M L-asparagine, supplemented with 100 ng/ml both recombinant human GM-CSF and IL-4 (PeproTech, Rocky Hill, NJ) or left unstimulated in 6-well plates (17, 19) . In some experiments, neutralizing Ab for human (h)M-CSF (1 g/ml; goat polyclonal; R&D Systems, Minneapolis, MN) or a goat IgG control (Santa Cruz Biotechnology, Santa Cruz, CA) was added to DC cultures. Cells were incubated for 4 -5 days at 37°C under 5% CO 2 . After 3 days of culture, 1.5 ml of supernatant was removed and replenished with fresh medium containing IL-4 and GM-CSF. The cells were harvested on the fifth day. Supernatants were used for IL-10 evaluation, whereas cells were analyzed with flow cytometry by staining with anti-CD1a, anti-HLA-DR, anti-CD83, and anti-CD86. Apoptosis of DC was measured using Annexin V-FLUOS staining kits according to the manufacturer's instructions (Roche Molecular Biochemicals, Indianapolis, IN). The Ag-presenting capabilities of cultured M or DC were assessed by activity in MLR and production of immunostimulatory monokines. In the MLR, 1 ϫ 10 4 M or DC were cocultured with 1 ϫ 10 5 cells/well allogenic T cells. The plates were incubated at 37°C under 5% CO 2 for 5 days, and then pulsed with 1 Ci/well of [H 3 ]thymidine for 24 h and harvested. The monokine production was evaluated after stimulation with 100 IU/ml IFN-␥ and 0.5 g/ml staphylococcal enterotoxin B (SEB) for 18 h. The supernatants were collected and assessed for IL-12 and IL-15 production by ELISA.
Some iDC were cultured an additional 3 days in TNF-␣ (100 IU/ml; PeproTech), IL-4 (100 IU/ml; PeproTech), and GM-CSF (100 IU/ml; PeproTech). Cells were harvested, and mature DC (mDC) were enumerated with anti-CD83 (BD PharMingen).
The DC of patients were defined as immuno-nonstimulatory (dysfunctional) when the MLR of IL4/GM-CSF-differentiated M was Ͻ33% of normal control value. In the initial analysis, MLR from unstimulated M was calculated as a percentage of normal.
Flow cytometric analysis
Mouse mAb recognizing human CD1a (clone BL6; Coulter, Brea, CA), CD11c (clone B-ly6; BD PharMingen), CD33 (clone P67.6; BD PharMingen), CD83 (clone HB15e; BD PharMingen), CD86 (clone 2331; BD PharMingen), HLA-DR (clone G46-6; BD PharMingen), and CD126 (clone M91; Immunotech, Marseille, France) were used. A rat anti-human CD115 (clone 7-7A3-17; Lab Vision, Fremont, CA) was detected by secondary anti-rat PE-conjugated Ab-defined CD115 (Serotec, Raleigh, NC). A total of 1 ϫ 10 5 cells incubated with conjugated mAb or the appropriate isotype controls in recommended dilutions or in pretitrated amounts (CD115, CD126) was washed twice with PBS containing 2% FBS and resuspended in 500 l for two-or four-color analysis after appropriate compensation adjustments. M IL-4R and GM-CSFR␣ expression was tested by using specific fluorokine kits (R&D Systems) and analyzed on a Coulter XL or FACSCalibur.
RNase protection assay (RPA)
A total of 1 ϫ 10 6 4ϩGM-treated DC from controls and patients were treated for 8 -10 h with SEB (0.5 g/ml) plus IFN-␥ (100 IU/ml). Total cytoplasmic RNA was isolated using Tri-reagent (Molecular Research Center, Cincinnati, OH). Antisense probes for quantification of RNA for hIL-10, hIL-12 p35 and p40, hIL-15, and hIL-6 were labeled with [ 32 P]UTP using Riboquant in vitro transcription kit (BD PharMingen). The band intensities of RPA gels were quantified using NIH Image software and adjusted for loading irregularities by comparison to the ribosomal gene product L32.
ELISA-based cytokine detection assays
Cytokine levels in culture supernatants were measured using cytokine-specific ELISA according to the manufacturer's guidelines. The lower limits of detection for the assays were as follows: IL-12p70 plus p40, Ͻ5 pg/ml; IFN-␥, Ͻ2 pg/ml; IL-10, Ͻ3 pg/ml (all from Endogen, Woburn, MA); IL-4, Ͻ1.25 pg/ml; GM-CSF, Ͻ0.27 pg/ml (BioSource International, Camarillo, CA); and M-CSF, Ͻ25 pg/ml (R&D Systems).
Statistical analysis
Due to the nonparametric distribution of the studied variables, the primary tests performed were the Kruskal-Wallis H and Mann-Whitney U tests for comparisons of the nonparametric variables. One-way ANOVA with least significant differences test and Student's t test were performed when the effect of neutralizing Ab on DC generation was studied due to the parametric distribution of the studied variables confirmed by the Lavene test. A regression analysis was computed by the stepwise method. Statistical significance was set at a two-tailed value of p Ͻ 0.05. SPSS version 8.0 software was used for all calculations.
Results
Segregation of trauma patient M data on the basis of altered M functions
Our data indicated that the M of severely injured patients, as a group, have depressed MLR levels compared with M of normal controls. However, the M responses of the severely injured patient group could be segregated into those with essentially normal MLR induction capacity (high MLR inducing) and those with a dramatically reduced MLR immunostimulatory capacity which was Ͻ33% of paired normal control (Fig. 1A) . Patient M with low MLR-inducing capacity also had significantly reduced IL-12 production (Fig. 1A) as described previously (7) (8) (9) . However, patient M retaining high MLR-inducing capacity also maintained IL-12 production (Fig. 1A) . Patients whose M had low MLRinducing capacity also developed T cell anergy as evidenced by a failure of their simultaneously isolated T lymphocytes to proliferate in response to direct TCR stimulation (immobilized anti-CD3 plus anti-CD4) ( Table I) . As previously described, this T cell anergy was also reflected in a failure to produce IL-4, IFN-␥, or GM-CSF (Table I ) (30) . Finally, the patients with APC-dysfunctional MLR did not show a significant correlation with their initial ISS. However, patients with low MLR-stimulatory M had significantly increased incidence of clinical pathology as indicated by a mean Marshall MODS score of 8.5, where a score of Ͼ6 indicates significant organ failure ( p Ͻ 0.05; Table II ) (29) . This suggested that postinjury M APC dysfunctions may contribute to trauma patient pathology. Using these M MLR-based segregation categories, patient M with low or high MLR were assessed for M-to-iDC conversion.
Patient M differentiation to iDC
Well-established M APC dysfunction in trauma patients could partially result from failed M-to-DC differentiation. Other studies of immunosuppressed patients with APC defects identified a reduction in M CD11c ϩ DC precursors numbers concurrent with increases in more Mac-like M but normal in vitro 4ϩGM-induced differentiation of M to iDC (26, 27) . As seen in Fig. 1B , no decrease in CD11c precursor numbers was detected in populations of trauma patient M that were identified as having low MLRinducing capacity (APC defect), indicating a normal level of released precursors. However, these low MLR-inducing M did show increased expression of the Mac phenotype marker CD64 (Fig. 1B) . This more Mac phenotype of circulating M could indicate an altered M differentiation potential. 4ϩGM-induced M-to-iDC differentiation was compared among M of trauma patients with low MLR induction, M of trauma patients with high MLR induction, and control M. The differentiation of M to iDC indicated by the acquisition of CD1a expression was significantly depressed only in the low APC-capacity patient M ( Fig. 2A) .
Development of mDC APC capacity during interaction with allogenic T cells in MLR
Many of the described normal characteristics of in vitro M-to-DC differentiation were evident in our trauma patient M culture systems. Five-day in vitro culture of human M with 4ϩGM induces differentiation only to iDC, not to mDC (18 -22) . Our 4ϩGM-cultured M populations showed in controls an iDC expression of CD83 (DC maturation marker) of 1.37% positive (mean) after 5 days of culture, whereas patient 4ϩGM-cultured M were 5.36% CD83 ϩ positive in MLR-high populations and 2% CD83 ϩ positive in MLR-low populations. Human iDC in allogenic MLR cultures are stimulated by the control allogenic T cells to mature to potent APC (34) . Similarly, DC of controls induced a median T cell proliferation in the MLR of 22,845 dpm compared with 1,506 dpm for the MLR cultures of undifferentiated M (Fig. 1A) . The high MLR-inducing M of patients that differentiated to iDC showed a similar allogenic MLR-induced maturation, stimulating 16,057 dpm of T cell proliferation vs 1,208 for the M. In contrast, patient M with low-MLR capacity not only failed to differentiate to CD1a ϩ iDC but also showed only minimal increases in MLRinducing capacity when cultured with allogenic T cells ( Fig. 2A) . Although the MLR-inducing capacity of patient M was highly correlated with the ability of their 4ϩGM-cultured M to mature from iDC to highly competent APC in a subsequent allogenic MLR, there was a greater degree of MLR depression than reduced CD1a expression (Fig. 2B) .
Characteristics of APC-dysfunctional patient 4ϩGM-cultured M
Because the MLR defect of 4ϩGM-cultured M was greater than the depressed CD1a expression of 4ϩGM-cultured M, we resegregated the patient M data on the basis of MLR dysfunction after culture with 4ϩGM. This data analysis included both M with a dysfunctional differentiation to iDC and those with iDC maturation defects. Using this more inclusive criteria, the difference in CD1a differentiation between the low-and high-MLR-inducing cells of patients was even more striking ( Fig. 3A compared with Fig. 2A) .
A variation in 4ϩGM-induced CD1a differentiation was observed in the high MLR patient M population, ranging from a low of 50% of control CD1a conversion (illustrated by the Fig. 3A flow cytometry profile) to a high of 110% of control. In contrast, CD1a levels of low MLR-inducing 4ϩGM-cultured M were uniformly depressed, often almost negative (Fig. 3A) . Similarly, the HLA-DR expression of low MLR-inducing iDC failed to increase (Fig. 3B) , and the up-regulation of the costimulatory molecule CD86 by these cells was depressed (Fig. 3C ) in both the total percentage of positive cells and the ligand expression density (mean fluorescence intensity (MFI)). These data explain some of the reduced MLR capacity of these 4ϩGM-cultured patient M.
Other immunostimulatory defects of these 4ϩGM-induced patient M included a reduced production of IL-12 even after additional stimulation with SEB plus IFN-␥, which should have matured any DC through Toll-like receptor 2 activation (Fig. 4A) . IL-15 levels were also reduced in this system (data not shown). This reduced IL-12 and IL-15 production was also detectable at the mRNA level and was not the result of reduced viability, because the housekeeping ribosomal protein gene L32 was unaffected (Fig. 4B) .
Possible contributors to the failure of trauma patients to develop DC with potent APC function
4ϩGM-induced M-to-DC differentiation can be altered by numerous microenvironmental changes (28) . Although increased IL-10 production inhibits M-to-DC differentiation, low-MLR capacity 4ϩGM-cultured patient M had reduced IL-10 at both the mRNA (Fig. 4B ) and protein levels (Fig. 4C) . Increased DC apoptosis during differentiation could contribute to a DC differentiation defect. In fact, the low MLR-inducing 4ϩGM-cultured M of patients did have significantly increased apoptosis compared with controls after a 5-day culture period. However, the patient M with high MLR-inducing capacity also showed increased apoptosis during 5-day culture (Fig. 4C) . Decreased GM-CSF stimulation can decrease M-to-iDC differentiation (25) . Although all cultures had similar exogenous GM-CSF added, the expression of the GM-CSFR on patient M with low-MLR capacity was significantly reduced, perhaps reducing efficiency of the GM-CSF induction (Fig. 5) . IL-4 is necessary to drive M to iDC (19) . A reduced ratio of IL-4 to GM-CSF can result in a failure of M to convert to iDC in a timely fashion (25, 35, 36, 37) . Again, although added IL-4 concentrations were constant, the levels of M IL-4R expression were significantly reduced on low MLR-capacity M.
Finally, the differentiation of human M to iDC is finely balanced against their differentiation to activated Mac (21, (23) (24) (25) . M-CSF drives M differentiation to Mac and inhibits GM-CSFR expression and iDC differentiation (19, (23) (24) (25) . Other cytokines like IL-6, which up-regulate the M-CSFR (CD115), cooperate with M-CSF to increase M-to-Mac differentiation (23) (24) (25) . Patient M with low or high DC MLR induction capacity were compared with control M for production of M-CSF and expression of both the IL-6R (CD126) and the M-CSFR (CD115). The median expression of CD115 of control M was 5.1% positive (Fig. 6A and Table III ). Patients whose 4ϩGM M had induced higher levels of proliferation in the MLR had a median CD115 expression of 3.8% positive. In contrast, 40% of low DC MLR M were CD115 positive. Interestingly, the M that showed low DC MLR function had similar CD126 expression (44.1% positive) to that of control M (33.4% positive), but those trauma patient M that could differentiate into iDC with high MLR-inducing capacity had downregulated their CD126 expression (19.5% positive). The difference in the M M-CSF production of the two patient groups was the most dramatic. Normal and patient M that could differentiate to potent DC APC produced significantly lower levels of M-CSF than did the patient M that failed to differentiate to MLR-inducing DC (Fig. 6B) . M production of M-CSF and their response to M-CSF seemed to highly influence eventual DC differentiation. Addition of Ab to M-CSF into 4ϩGM patient M cultures improved both their differentiation to CD1a ϩ iDC and their subsequent maturation to APC in allogenic MLR (Fig. 6C) .
Discussion
These data represent the first reexamination of the Ag-presenting function of M of posttrauma patients in several years and the first identification of a DC differentiation defect in trauma patients. Our data indicate that trauma patient M that are unable to support allogenic T cell proliferation in an MLR response are unable to differentiate into CD1a ϩ iDC under the influence of exogenous 4ϩGM. Unlike some previously detected patient DC defects, the posttrauma iDC defect does not result from a loss of circulating CD11c ϩ DC precursors, nor is it a universal result of injury. Patients whose M can function as APC in allogenic MLR also possess the capacity to differentiate to iDC. The CD1a ϩ iDC phenotype was not developed in 4ϩGM-cultured M of patients identified as MLR dysfunctional, nor was increased M CD86 or HLA-DR expression seen. The 4ϩGM-cultured patient DC maturation in response to subsequent SEB (assessed by increased IL-12 and IL-15 production) also failed to occur in the MLRdysfunctional M group, as did further DC maturation in an allogenic MLR subsequent to 4ϩGM cultures. Elevated in vivo IL-6 levels combined with high M-CSF levels favor M differentiation to Mac over M differentiation to DC (23, 25, 27, 38) . In vitro culture of human M with M-CSF differentiates them to Mac (19, 25, 39) . The APC-competent and APC-dysfunctional trauma patient M groups did not differ in their IL-6 levels (data not shown). However, elevated IL-6 levels are produced by numerous cell types in the postinjury microenvironment and would influence M-to-Mac differentiation in APC-dysfunctional patient M that do not down-regulate their CD126 (IL-6R) expression (40, 41) . The failure of APC-dysfunctional M to decrease CD126 expression would increase their sensitivity to elevated circulating IL-6 levels postinjury. In this study, patient M with low immunostimulatory capacity had increased Mac-like phenotype characteristics, such as increased CD64 expression, increased production of M-CSF, increased expression of the M-CSFR (CD115), and down-regulated GM-CSFR expression (31, 42, 43) . A postinjury increase in myeloid M-CSFR expression has also been recently reported in a FIGURE 3. Failure to increase MLR induction after 4ϩGM culture indicates a more severe M differentiation defect. A, Fresh M were stimulated with IL-4 plus GM-CSF (100 ng/ml each) for 5 days, and the cells were assessed for CD1a expression by flow cytometry as well as for their ability to induce proliferation of allogenic T cells in an MLR setup, as described in Materials and Methods. The patient 4ϩGM-treated M data was resegregated based on the allogenic MLRinducing capacity of 4ϩGM-treated M (iDC) (low MLR-inducing iDC were Յ33% of control value, whereas high MLR-inducing iDC were Ͼ33% of control value). A, CD1a expression was reanalyzed based on this division. The patients' individual iDC CD1a percent positive data from the low MLR group (n ϭ 21), high MLR induction group (n ϭ 16), and normals (n ϭ 34) are presented with the median shown as a bar. ϩ inflammatory Macs have been previously described in injury, and these more inflammatory Mac have altered function (41, 44 -46) . We have previously reported that trauma patient M with high CD64 expression produce exaggerated amounts of the 26-kDa, cell-associated form of TNF-␣ with increased TNF-␣ mRNA stability (1, 47) . A recent report describes hM-CSF-differentiated PBMC Mac as producing higher TNF levels than M because of their increased TNF mRNA stability. These data additionally suggest a shift toward a more Mac-like phenotype for circulating, aberrant M populations of trauma patients (48) . Finally, both M-to-iDC differentiation and the subsequent MLR-inducing capacity were improved if anti-M-CSF was added to patient M 4ϩGM cultures, supporting the contribution of M-CSF to the DC defect of the patients. However, additional M-CSF effects on DC function, besides blocking Mto-iDC differentiation, have been described. Appropriate DC MHC class II expression is also altered by M-CSF exposure (38) . Consequently, the iDC MLR increases after anti-M-CSF treatment could reflect improved MHC class II levels as well as improved M-to-iDC differentiation.
The data in this study do not address the full component of DC APC defects or mechanisms inducing APC dysfunction that could be occurring postinjury. The 4ϩGM M-derived iDC population represents both future interstitial DC and future Langerhans DC depending on received maturation signals (15, 19) . Although human PBMC M-derived DC appear to be potent APC, the subsets may have different capacities for T lymphocyte activation (15, 18, 31, 34) . Consequently, the detected difference in MLR-inducing capacity may be related to undetected shifts in patient DC subsets. TGF␤ matures Langerhans like DC. M TGF␤ levels are known to be increased in these immunoaberrant trauma patients, possibly increasing Langerhans like DC (46) . In two preliminary experiments, no increase in CD207 (the Langerhans marker) was detected on low MLR-capacity patient M, but these data are far from conclusive. A posttrauma increase in plasmacytoid or lymphoid-derived DC precursors could greatly affect overall DC APC capacity (15, 16, 49) . The plasmacytoid DC population is suggested to preferably induce regulatory T cells (15, 16) . However, our isolation technique selects only for myeloid DC, and therefore, A, 4ϩGM-induced M from patients (n ϭ 14, low-MLR capacity, and n ϭ 21, high-MLR capacity samples) and control samples (n ϭ 36; two outliers are Ͼ2500) were assessed for IL-12 production (tested by ELISA) after stimulation with SEB (0.5 g/ml) plus IFN-␥ (100 IU/ml) for 18 h. Data represent individual patient values with the median shown as a bar. ‫,ء‬ p Ͻ 0.05, compared with control. B, 4ϩGM-treated M (1 ϫ 10 6 cells) were stimulated for 8 -10 h in the presence of SEB (0.5 g/ml) plus IFN-␥ (100 IU/ml). Total cytoplasmic RNA was isolated and mRNA levels for IL-10, IL-12, and IL-15, as well as L32 (loading control), were assayed by multiprobe RPA. The data are representative of three experiments. C, Supernatants of 4ϩGM-cultured M of patients (n ϭ 18 (low MLR-inducing samples) and 28 (high MLR-inducing samples)) and controls (n ϭ 47) were tested for IL-10 levels by ELISA, while the cells were assessed for apoptosis by staining with Annexin V-FITC and analyzed by flow cytometry. ‫,ءء‬ p Ͻ 0.001, compared with normal control median value. Ranges are indicated. Skewness in low MLR IL-10 data, 2.41 Ϯ 0.54; skewness in Annexin-FITC samples, 1.14 Ϯ 0.69. the detected posttrauma defect is in the myeloid M DC population. Our examination of isolated patient M also does not address the in vivo T lymphocyte contribution to intensifying or prolonging a postinjury APC dysfunction. Diminished T cell IL-4 and/or IL-13 production due to postinjury T cell apoptosis would further intensify any in vivo M-to-iDC defect.
A defect in iDC-to-mDC development may also be occurring. There was a small (Ͻ10%) population of CD1a ϩ DC generated in the 4ϩGM-cultured M of some APC-dysfunctional patients. The APC defect was more apparent in the allogenic T cell MLR cultures of these patients' iDC (Fig. 2B) . Consequently, a DC maturation defect may also contribute to postinjury APC dysfunction. A recent report showed that septic but not simple trauma patients have increased in vivo levels of DC apoptosis in their lymph nodes, suggesting that the interdigitating DC may fail to respond to T cell maturation and/or survival signals (50) . No difference in apoptosis levels between APC-competent and APC-dysfunctional patient M during 4ϩGM cultures was detected. Both were increased. However, we did not assess apoptosis during the subsequent MLR. Increased apoptosis of the low MLR-capacity iDC populations during the MLR could have contributed to the more significant level of APC defects detected in this second culture period (Fig. 2B) .
The most significant difference seen in the low MLR-inducing patient M population and the high MLR-inducing patient M was their production of M-CSF and expression of M-CSFR. The failure of low MLR-inducing patient M to differentiate to iDC most closely paralleled their expression of more Mac-like characteristics such as increased CD64 ϩ , high M-CSFR expression, reduced GM-CSFR expression, low APC function, low IL-12 production, and high M-CSF production (31, 42) . Our previous publications, as well as those of others, suggest that posttrauma immunoaberrant M have increased Mac-like characteristics (44 -47) . The partial amelioration of the M-to-iDC differentiation defects in these low APC-capacity M of trauma patients after anti-M-CSF treatment suggest preferential Mac differentiation. The known posttrauma microenvironment contains increased circulating IL-6, PGE 2 , and gut-released LPS that can alter M receptor expression and preferentially induce M-CSF, thereby interfering with M-to-iDC differentiation while favoring inflammatory Mac development. A, Low and high MLR-inducing M from patients and controls were assessed for expression of CD115 (M-CSFR) and CD126 (IL-6R) by flow cytometry. Flow cytometry gates were set according to the isotype controls. The data are representative of 10 experiments. B, Fresh M from patients (n ϭ 12 (low MLR-inducing) and 11 (high MLR-inducing samples)) and controls (n ϭ 25) were stimulated with IL-4 plus GM-CSF (100 ng/ml each) for 5 days and the cells were assessed for M-CSF production (tested by ELISA) after stimulation with SEB (0.5 g/ml) plus IFN-␥ (100 IU/ml) for 18 h. C, Neutralizing Ab to M-CSF (1 g/ml) or isotype control was added to patient M (n ϭ 12) at the beginning of 4ϩGM treatment (5 days) followed by assessment of CD1a expression as well as MLR activity. Data are expressed as mean percent increases in MLR activity or CD1a expression. ‫,ء‬ p Ͻ 0.01, compared with normal control value.
